Insights
Concise explainers, with the evidence linked.
Expert notes on AI in clinical research, cardiovascular risk prediction, healthy ageing, clinical research consultancy and emerging therapeutics. Each note points to the original literature and trusted external sources.
AI in clinical research
AI in clinical research: what the evidence supports today
Machine learning is entering trials through recruitment, adjudication and monitoring, yet most tools still lack prospective evaluation. How to tell mature applications from promising ones, and what ethics committees and regulators now expect.
5 min read
Clinical research consultancy
When independent scientific advice helps a clinical research programme
Consultancy is not a contract research organisation and not regulatory affairs. Used at the right moments, it changes the questions a programme asks and the evidence it produces.
4 min read
Advanced hypertension therapeutics
Advanced hypertension therapeutics: angiotensinogen and aldosterone synthase in focus
Three new classes have reached late-phase trials: RNA silencing of angiotensinogen, aldosterone synthase inhibition and dual endothelin antagonism. This note separates mechanism, blood-pressure effect and outcome evidence, and says plainly where the last does not yet exist.
9 min read
Hypertension treatment
Potassium and blood-pressure treatment: the result that can change the plan
A potassium value arriving a few days after a successful dose increase can undo the decision that produced it. What the physiology predicts, what the AMBER trial did and did not establish, and why dietary potassium and serum potassium are different measurements.
9 min read
Treatment adherence
Before the fourth drug: investigating apparent treatment resistance
When blood pressure stays high on three prescriptions, the first unknown is how much of the prescribed treatment is reaching the patient. What urine drug testing can and cannot show, what the 2026 OUTREACH trial found when the result was fed back, and why adherence belongs in every hypertension trial's analysis plan.
9 min read
Oral and systemic health
Treating gum disease: what changes beyond the mouth?
Periodontitis keeps company with cardiovascular disease, but company is not causation. Two randomised trials measured what happens to the arteries and to blood pressure after intensive periodontal treatment. What they showed, what they could not show, and how a trial that aimed higher would need to be built.
9 min read
Healthy ageing
A younger biological age: what the test can actually tell us
A repeat test reports a biological age three years lower than a year ago. Before anyone celebrates, it is worth asking what was measured, how much of the change is noise, and why a clock that predicts disease in populations does not automatically validate a treatment that moves it.
9 min read
Insights are expert summaries for professionals. They are not medical advice and do not replace the cited sources.